LifeStance Health Group (Nasdaq: LFST) announced the pricing of a secondary public offering of 35 million shares at $8.15 per share. The company will not receive proceeds from the offering but has agreed to repurchase 6 million shares from the underwriter. The offering is expected to close on May 12, 2026, with J.P. Morgan serving as the underwriter.

LifeStance Health Group (NASDAQ: LFST) announced Q1 2026 results with revenue of $403.5 million, up 21% year-over-year, and net income of $14.2 million compared to $0.7 million in Q1 2025. The company increased its clinician base by 11% to 8,349 and raised full-year 2026 guidance for revenue, center margin, and adjusted EBITDA. The company also announced an outcomes study showing approximately 75% of 180,000 patients reported clinically significant improvement in anxiety and depression.

LifeStance Health Group director Robert Bessler sold 69,899 shares worth approximately $492,000 on April 23-24, 2026. The sale represented only 2.47% of his total holdings, with over 2.7 million shares retained indirectly. Analysts view this as non-concerning given Bessler's substantial remaining stake and the company's strong 2025 performance, which included 14% revenue growth and a turnaround to profitability.

The emotional counseling service market is projected to grow from $4.72 billion in 2025 to $21.21 billion by 2030, with a CAGR of 35%. Growth drivers include increased digital therapy adoption, rising mental health infrastructure investments, employer-sponsored services expansion, and focus on adolescent mental health. Leading companies are leveraging AI-based tools and tele-counseling platforms to enhance accessibility and personalized care.

The grief counseling market is projected to grow from $3.67 billion in 2025 to $5.83 billion by 2030 at a CAGR of 9.7%. Growth is driven by increased mental health awareness, expansion of digital support platforms, telehealth adoption, and rising demand for accessible bereavement care. Key players include Cleveland Clinic, LifeStance Health, VITAS Healthcare, and Talkspace.

Presidio appointed Paula Cipollone as Chief Transformation Officer to lead strategic operations and drive AI-powered transformation, focusing on streamlining operations and enhancing customer engagement.

LifeStance Health Group, Inc. reported strong Q1 2025 results, with revenue growth, positive net income, and increased Adjusted EBITDA. The company reiterated its full-year 2025 guidance.

LifeStance Health Group, Inc. reported strong financial results for the fourth quarter and full year 2024, with revenue growth of 16% and 19% respectively. The company also provided guidance for 2025, expecting revenue of $1.40 billion to $1.44 billion.

Wall Street analysts have set a mean price target of $7.93 for LifeStance Health, indicating a potential upside of 26.7%. However, investors should be cautious as price targets can be unreliable and analysts may have business incentives to set overly optimistic targets.

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, reports that management became aware of an unprecedented settlement between Anson Funds and the United States Securities and Exchange Commission dated June 11, 2024. Lifeist is in the process of carefully reviewing and considering the said settlement and examining all legal options with counsel. The Company will promptly report to shareholders at such time as we have made a determination with counsel. A copy of the settlement is publicly available at https://www.sec.gov/files/litigation/admin/2024/ia-6622.pdf.

The heavy selling pressure might have exhausted for LifeStance Health (LFST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Mikra completes design of new product that delivers superior clarity of cognition and improved memory in collaboration with Jose Bautista and advances shipment date